Skip to content

Sun Y, et al. A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial. Lancet. 2022;399:1964-1975. PMID 35500594

One-paragraph summary

The China Rural Hypertension Control Project randomised 326 villages (163 intervention, 163 enhanced usual care), stratified by province, county and township, enrolling 33,995 people aged ≥40 with untreated blood pressure ≥140/90 mm Hg (≥130/80 with cardiovascular disease, diabetes or chronic kidney disease) or treated pressure ≥130/80 mm Hg. In intervention villages, trained village doctors — community health workers at the front line of primary care — initiated and titrated antihypertensive medication according to a standard protocol under supervision from primary care physicians, and delivered coaching on home monitoring, lifestyle and adherence. At 18 months, 57.0% of 15,414 intervention participants versus 19.9% of 14,500 control participants had blood pressure below 130/80 mm Hg — a difference of 37.0 percentage points (95% CI 34.9–39.1; p<0.0001). Mean systolic pressure fell 26.3 mm Hg (95% CI 25.4–27.1) versus 11.8 mm Hg (11.0–12.6), a group difference of −14.5 mm Hg (−15.7 to −13.3), with diastolic falls of 14.6 versus 7.5 mm Hg. No treatment-related serious adverse events were reported in either group.

Key findings

  • A 37-percentage-point absolute difference in control — among the largest effects on a control endpoint in the hypertension literature.
  • A 14.5 mm Hg systolic separation, roughly three times what a single additional drug typically delivers.
  • Achieved by non-physician prescribing under protocol, not by any new drug or device.
  • No treatment-related serious adverse events despite aggressive titration to a <130/80 mm Hg target in a rural, largely older population.
  • Delivered in a setting with limited specialist access, which is where the global burden is concentrated (PMID 31327566).

Limitations

  • Open-label; outcome assessment of blood pressure is objective but not blinded, and the Hawthorne effect on the intervention villages cannot be excluded.
  • The 2022 report's endpoint was blood-pressure control. The subsequently published 36-month outcome report found cardiovascular events at 1.62% versus 2.40% per year (HR 0.67, 95% CI 0.61–0.73) and all-cause-death HR 0.85 (0.76–0.95), with more hypotension (PMID 36871573). Seven-year follow-up retained lower cardiovascular-event rates overall (HR 0.76, 0.72–0.81) and during the three-year post-trial period (0.79, 0.73–0.85), while hypotension and mild hypokalaemia were more frequent (PMID 42666029).
  • The intervention is multifaceted — protocol, supervision, coaching, home monitoring, medication supply — so the active ingredient cannot be isolated from this design.
  • Village doctors in China have a defined role in an existing rural cooperative medical scheme; the model's transferability depends on an equivalent cadre existing elsewhere.
  • Enhanced usual care in the control arm may still exceed routine care, which would bias toward the null rather than away from it.

Why it matters

The central finding of this condition is that efficacy has never been the binding constraint — control rates are 23% and 18% globally while the pharmacology has worked for fifty years (PMID 34450083). CRHCP is the strongest single demonstration that the constraint is deliverable, now with cardiovascular outcomes at three and seven years (PMIDs 36871573, 42666029). Together with the barbershop trial (PMID 29527973), HOPE 4 (PMID 31488369) and the Kaiser Permanente programme (PMID 23989679), it defines a consistent pattern: replace clinician discretion with a protocol, move care to where the patient already is, and remove the cost or access barrier. What none of these trials has done is test their components against each other, so the active ingredient remains unidentified.

Cited by wiki pages

  • overview
  • adherence and implementation
  • epidemiology and burden